Global markets surged this week as fears of an impending US recession were quashed. With the risk atmosphere now feeling significantly calmer, I’m revisiting some FTSE 100 stocks I’ve been hesitant to buy.
GSK
I’ve been hemming and hawing about buying GSK (LSE: GSK) for so long now it’s become an internal joke with myself. I’ll probably be in the 50-59 age bracket that its Arexvy vaccine was recently approved for before I finally buy!
It’s one of the few FTSE 100 mega-caps that have managed to elude my profile thus far. But its recent Q2 results placed it firmly back in my crosshairs.
A 31 July report revealed sales up 13%, a 5.2% improvement on analysts expectations. Subsequently, core operating profit rose 18% with earnings per share (EPS) up 13%. Future return on equity (ROE) is now forecast to be 39% in three years.
A promising option — but one pressing concern could derail the progress.
GSK’s…
